Atef Zaher

468 total citations
11 papers, 191 citations indexed

About

Atef Zaher is a scholar working on Physiology, Rheumatology and Organic Chemistry. According to data from OpenAlex, Atef Zaher has authored 11 papers receiving a total of 191 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 4 papers in Rheumatology and 3 papers in Organic Chemistry. Recurrent topics in Atef Zaher's work include Lysosomal Storage Disorders Research (8 papers), Glycogen Storage Diseases and Myoclonus (4 papers) and Carbohydrate Chemistry and Synthesis (3 papers). Atef Zaher is often cited by papers focused on Lysosomal Storage Disorders Research (8 papers), Glycogen Storage Diseases and Myoclonus (4 papers) and Carbohydrate Chemistry and Synthesis (3 papers). Atef Zaher collaborates with scholars based in United States, Canada and France. Atef Zaher's co-authors include Fred Saad, Yang Bai, Ted P. Szatrowski, Ada Gjyrezi, Daniel Worroll, Katsuhiro Kita, Emmanuel S. Antonarakis, Shinsuke Tasaki, Paraskevi Giannakakou and David M. Nanus and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Atef Zaher

11 papers receiving 191 citations

Peers

Countries citing papers authored by Atef Zaher

Since Specialization

Citations

This map shows the geographic impact of Atef Zaher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atef Zaher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atef Zaher more than expected).

Fields of papers citing papers by Atef Zaher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atef Zaher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atef Zaher. The network helps show where Atef Zaher may publish in the future.

Co-authorship network of co-authors of Atef Zaher

This figure shows the co-authorship network connecting the top 25 collaborators of Atef Zaher. A scholar is included among the top collaborators of Atef Zaher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atef Zaher. Atef Zaher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease 2024 ·Clinical Pharmacology & Therapeutics ·Chanchala Kaddi, (unknown), (unknown), (unknown), Hugo Geerts, Piet H. van der Graaf, Julie L. Batista, Meredith C. Foster, Catherine Ortemann‐Renon, Atef Zaher, Kristina An Haack, (unknown)	5
2	P374 COMET: effects of avalglucosidase alfa and treatment switch from alglucosidase alfa on week 145 QMFT individual item responses 2023 ·Neuromuscular Disorders ·Priya S. Kishnani, (unknown), Kristina An Haack, N. Armstrong, Magali Periquet, (unknown), Atef Zaher, Benedikt Schoser	1
3	Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report 2022 ·Genetics in Medicine ·Priya S. Kishnani, David Kronn, Anaïs Brassier, Alexander Broomfield, James Davison, Si Houn Hahn, Satoko Kumada, François Labarthe, Hirotaka Ohki, (unknown), S. Grace Prakalapakorn, Kristina An Haack, Barbara Kittner, (unknown), Susan Sparks, Catherine Wilson, Atef Zaher, Yin‐Hsiu Chien	28
4	Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study 2022 ·Molecular Genetics and Metabolism ·Patrick Deegan, Özlem Göker-Alpan, Tarekegn Geberhiwot, Robert J. Hopkin, Elena Lukina, Anna Tylki‐Szymańska, Atef Zaher, (unknown), Sebastiaan J.M. Gaemers, Vijay Modur, Beth L. Thurberg, Jyoti Sharma, Behzad Najafian, Michael Mauer, Pronabesh DasMahapatra, William R. Wilcox, Dominique P. Germain	33
5	Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline 2022 ·Molecular Genetics and Metabolism ·David Kronn, James Davison, Anaïs Brassier, Alexander Broomfield, Si Houn Hahn, Satoko Kumada, François Labarthe, Hirotaka Ohki, S. Grace Prakalapakorn, Kristina An Haack, (unknown), Susan Sparks, Swathi Tammireddy, Catherine Wilson, Atef Zaher, Tianyue Zhou, Yin‐Hsiu Chien, Priya S. Kishnani	1
6	OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa 2022 ·Genetics in Medicine ·David Kronn, James Davison, Anaïs Brassier, Alexander Broomfield, Si Houn Hahn, Satoko Kumada, François Labarthe, Hirotaka Ohki, S. Grace Prakalapakorn, Kristina An Haack, (unknown), Susan Sparks, (unknown), Catherine Wilson, Atef Zaher, Tianyue Zhou, Yin‐Hsiu Chien, Priya S. Kishnani, (unknown)	6
7	Baby-COMET methodology: A clinical study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of avalglucosidase alfa in treatment-naïve participants with IOPD 2022 ·Molecular Genetics and Metabolism ·Alexander Broomfield, James Davison, Maria Alice Donati, Kristina An Haack, Swathi Tammireddy, Nathan Thibault, Michael Woloschak, Atef Zaher, Tianyue Zhou, Andreas Hahn	1
8	Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment 2020 ·Molecular Genetics and Metabolism ·Beth L. Thurberg, George A. Díaz, Robin Lachmann, Thomas D. Schiano, Melissa Wasserstein, Allena Ji, Atef Zaher, Michel Peterschmitt	25
9	P0062GLUCOSYLCERAMIDE SYNTHASE INHIBITION WITH VENGLUSTAT IN CLASSIC FABRY DISEASE PATIENTS LEADS TO PROGRESSIVE REDUCTION OF ENDOTHELIAL CELL GLOBOTRIAOSYLCERAMIDE INCLUSION VOLUME 2020 ·Nephrology Dialysis Transplantation ·Michael Mauer, Özlem Göker-Alpan, Dominique P. Germain, William R. Wilcox, Robert J. Hopkin, Elena Lukina, Tarekegn Geberhiwot, Patrick Deegan, Anna Tylki‐Szymańska, (unknown), Atef Zaher, Eric Hailman, Vijay Modur, Behzad Najafian	1
10	Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY 2018 ·Clinical Cancer Research ·Scott T. Tagawa, Emmanuel S. Antonarakis, Ada Gjyrezi, Giuseppe Galletti, (unknown), Daniel Worroll, John A. Stewart, Atef Zaher, Ted P. Szatrowski, Karla V. Ballman, Katsuhiro Kita, Shinsuke Tasaki, Yang Bai, Luigi Portella, Brian J. Kirby, Fred Saad, Mario A. Eisenberger, David M. Nanus, Paraskevi Giannakakou	86
11	TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2016 ·Journal of Clinical Oncology ·Scott T. Tagawa, Emmanuel S. Antonarakis, Fred Saad, Marie Vanhuyse, Guru Sonpavde, Scott North, Costantine Albany, Che‐Kai Tsao, John A. Stewart, Atef Zaher, Ted P. Szatrowski, Wei Zhou, Giuseppe Galletti, Daniel Worroll, Mario A. Eisenberger, David M. Nanus, Paraskevi Giannakakou	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact